CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 44 enrolled
Drug / intervention
High dose of peanuts +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04415593
NCT04415593N/ACompleted
CompareCT.gov

High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety

Medical University of Warsaw·interventional·Posted Jun 4, 2020·Updated Dec 8, 2025

In Brief

A clinical study evaluating High dose of peanuts and Low dose of peanuts for Peanut Allergy. Completed, enrolled 44 participants across 1 site.

Detailed Summary

In this trial the investigators aim to assess the effectiveness and safety of oral immunotherapy with peanut protein in high and low dose (300mg versus 150mg) in children with peanuts allergy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeanut Allergy
CountriesPoland
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJun 4, 2020
Enrollment StartSep 1, 2020
Primary CompletionMay 30, 2024
Study CompletionJul 30, 2024
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 6.1 years ago

Interventions

High dose of peanutsdietary

Patients will receive a high dose of ground peanuts (300 mg) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product

Low dose of peanutsdietary

Patients will receive a low dose of ground peanuts (150 mg) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product